Mesoblast Limited

Equities

MSB

AU000000MSB8

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:52 2024-04-24 am EDT			5-day change	1st Jan Change
0.915 ^AUD	+1.67%		+22.00%	+195.16%

Apr. 01	ADRs End Higher; Connect Biopharma Climbs 26%	DJ
Mar. 28	ADRs End Lower; NuCana Slides 15%	DJ

Mesoblast Limited : - Release of shares from voluntary escrow

July 30, 2021 at 11:43 am EDT

Mesoblast Limited (ASX Code: MSB) gives notice in accordance with ASX Listing Rule 3.10A that 212,244 ordinary shares, which are subject to voluntary escrow arrangements, will be released from escrow on 6 August 2021.

Contact:

Tel: 1 800 89 6376

Latest news about Mesoblast Limited

ADRs End Higher; Connect Biopharma Climbs 26%	Apr. 01	DJ
ADRs End Lower; NuCana Slides 15%	Mar. 28	DJ
ADRs End Lower; Quhuo Drops 53%	Mar. 26	DJ
FDA Says Mesoblast Trial Data Sufficient to Support BLA Submission	Mar. 26	MT
Sector Update: Health Care Stocks Advance Late Afternoon	Mar. 26	MT
Top Midday Gainers	Mar. 26	MT
Sector Update: Health Care Stocks Steady Premarket Tuesday	Mar. 26	MT
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading	Mar. 26	MT
Top Premarket Gainers	Mar. 26	MT
Mesoblast Shares Jump After FDA Nod for Submission of Remestemcel-L Application	Mar. 26	DJ
Mesoblast to Resubmit Application for Potential Pediatric Treatment of Graft Versus Host Disease; Shares Gain Pre-Bell	Mar. 26	MT
United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease	Mar. 25	CI
Mesoblast Limited(ASX:MSB) added to S&P/ASX Emerging Companies Index	Mar. 17	CI
Mesoblast Raises AU$97 Million From Entitlement Offer, Institutional Placement	Mar. 14	MT
Mesoblast Raises AU$97 Million for Phase Three Registration Trials	Mar. 14	MT
Sector Update: Health Care Stocks Softer Late Afternoon	Mar. 11	MT
Sector Update: Health Care Stocks Decline in Afternoon Trading	Mar. 11	MT
Sector Update: Health Care	Mar. 11	MT
Top Stories at Midday: Bally's Gets Takeover Proposal; Eli Lilly's Eczema Study Results; Reddit's Expected IPO Price Range; FDA Backs Mesoblast Heart Therapy's Approval Pathway	Mar. 11	MT
Sector Update: Health Care Stocks Lean Lower Premarket Monday	Mar. 11	MT
Mesoblast Says FDA Supports Accelerated Approval Pathway for Heart Failure Treatment	Mar. 11	MT
Mesoblast Secures Backing from US FDA for Potential Fast-Track Approval of Heart Failure Treatment	Mar. 11	MT
Mesoblast Limited Announces United States Food & Drug Administration Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with A Left Ventricular Assist Device	Mar. 10	CI
Mesoblast Narrows H1 FY24 Loss; Shares Down 3%	Feb. 28	MT
Transcript : Mesoblast Limited, Q2 2024 Earnings Call, Feb 28, 2024	Feb. 28

Chart Mesoblast Limited

Duration

Period

More charts

Company Profile

Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Companyâs Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Companyâs licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.

Sector

Biotechnology & Medical Research

Calendar

2024-05-28 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Mesoblast Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.915 AUD

Average target price

1.1 AUD

Spread / Average Target

+20.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MESOBLAST LIMITED	+195.16%	678M
IQVIA HOLDINGS INC.	+0.82%	43.84B
MODERNA, INC.	+5.32%	41.68B
LONZA GROUP AG	+45.55%	41.25B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+6.14%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-25.47%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.98%	12.29B
MEDPACE HOLDINGS, INC.	+25.04%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.08%	11.15B

Other Biotechnology & Medical Research